Kimberly-Clark Acquires Kenvue

November 3, 2025

Kimberly-Clark agreed to acquire Kenvue, the Johnson & Johnson spin-off that owns Tylenol, Neutrogena, BAND-AID and other consumer health brands, in a cash-and-stock transaction valued at about $48.7 billion. The deal will combine major consumer-health and personal-care portfolios under Kimberly-Clark and is expected to generate pro forma 2025 net revenues of roughly $32 billion.

Buyers
Kimberly-Clark
Targets
Kenvue
Location
New Jersey, United States
Transaction Type
Buyout

Explore More

Related Acquisitions

Track M&A activity that matters to you

Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.